Blog

Model smarter, not harder: How Phoenix Cloud puts the science back at the center of modeling

Certara Model Designer brings cloud based pharmacometric modeling to your browser, with a curated model…

Arjen BosJuly 16, 2026

Publication

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis

Explore how model-based meta-analysis supports dose optimization, trial design, and regulatory decisions, plus emerging roles…

CertaraJuly 16, 2026

Blog

When to conduct hepatic impairment studies and when modeling may be enough

How to decide if a hepatic impairment study is required, choose the right study design,…

Zoe BarterJuly 13, 2026

Conference

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Matt Zierhut, PhD MBAJuly 9, 2026

Webinar

Integrated mechanistic modeling approaches in oncology drug development

CertaraJuly 8, 2026

Blog

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…

Hunter Stephens, PhDJuly 7, 2026

On-Demand Webinar

The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors

Learn how PBPK and QSP modeling support faster drug development by enabling smarter dose selection,…

CertaraJuly 1, 2026

Blog

Enhancing clinical trials with real-world evidence in pregnancy research

Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…

Alekhya Lavu, PhD, PharmDJune 26, 2026

Poster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

CertaraJune 23, 2026

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Model Informed Drug Development

Model smarter, not harder: How Phoenix Cloud puts the science back at the center of modeling

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis

When to conduct hepatic impairment studies and when modeling may be enough

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Integrated mechanistic modeling approaches in oncology drug development

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors

Enhancing clinical trials with real-world evidence in pregnancy research

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Newsletter sign up

Quick links

Solutions

Contact